Aelis Farma S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AELIS.PA research report →
About the company
Aelis Farma S. A. , a French biotechnology company founded in 2013 and headquartered in Bordeaux, is dedicated to the discovery and development of treatments for brain-related illnesses.
- CEO
- Pier Vincenzo Piazza
- IPO
- 2022
- Employees
- 28
- HQ
- Bordeaux, FR
Price Chart
- Market Cap
- $13.32M
- P/E
- -2.08
- P/S
- 6.39
- P/B
- 3.03
- EV/EBITDA
- -1.46
- Div Yield
- 0.00%
- Gross Margin
- 35.80%
- Op Margin
- -354.37%
- Net Margin
- -308.73%
- ROE
- -121.94%
- ROIC
- -59.16%
- Revenue
- $2.08M · -22.18%
- Net Income
- $-6,434,000 · 13.71%
- EPS
- $-0.47 · 12.96%
- Op Income
- $-8,281,000
- FCF YoY
- 54.03%
- 52W High
- $2.30
- 52W Low
- $0.67
- 50D MA
- $1.21
- 200D MA
- $1.23
- Beta
- 0.60
- Avg Volume
- 26.67K
Get TickerSpark's AI analysis on AELIS.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our AELIS.PA coverage
Recent articles, reports, and earnings notes.
No research on AELIS.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AELIS.PA report →Similar companies
Peers in the same neighborhood.